Cargando…

Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome

OBJECTIVE: Advanced glycation end products (AGEs) have pathophysiological implications in cardiovascular diseases. The aim of our study was to evaluate the prognostic value of fluorescent AGEs and its soluble receptor (sRAGE) in the context of acute coronary syndrome (ACS), both in-hospital phase an...

Descripción completa

Detalles Bibliográficos
Autores principales: Raposeiras-Roubín, Sergio, Rodiño-Janeiro, Bruno K., Paradela-Dobarro, Beatriz, Grigorian-Shamagian, Lilian, García-Acuña, José M., Aguiar-Souto, Pablo, Jacquet-Hervet, Michel, Reino-Maceiras, María V., González-Juanatey, José R., Álvarez, Ezequiel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772878/
https://www.ncbi.nlm.nih.gov/pubmed/24058542
http://dx.doi.org/10.1371/journal.pone.0074302
_version_ 1782284378537197568
author Raposeiras-Roubín, Sergio
Rodiño-Janeiro, Bruno K.
Paradela-Dobarro, Beatriz
Grigorian-Shamagian, Lilian
García-Acuña, José M.
Aguiar-Souto, Pablo
Jacquet-Hervet, Michel
Reino-Maceiras, María V.
González-Juanatey, José R.
Álvarez, Ezequiel
author_facet Raposeiras-Roubín, Sergio
Rodiño-Janeiro, Bruno K.
Paradela-Dobarro, Beatriz
Grigorian-Shamagian, Lilian
García-Acuña, José M.
Aguiar-Souto, Pablo
Jacquet-Hervet, Michel
Reino-Maceiras, María V.
González-Juanatey, José R.
Álvarez, Ezequiel
author_sort Raposeiras-Roubín, Sergio
collection PubMed
description OBJECTIVE: Advanced glycation end products (AGEs) have pathophysiological implications in cardiovascular diseases. The aim of our study was to evaluate the prognostic value of fluorescent AGEs and its soluble receptor (sRAGE) in the context of acute coronary syndrome (ACS), both in-hospital phase and follow-up period. METHODS: A prospective clinical study was performed in patients with debut’s ACS. The endpoints were the development of cardiac events (cardiac deaths, re-infarction and new-onset heart failure) during in-hospital phase and follow-up period (366 days, inter-quartile range: 273–519 days). 215 consecutive ACS patients admitted to the coronary care unit (62.7±13.0 years, 24.2% female) were included. 47.4% had a diagnosis of ST segment elevation myocardial infarction. AGEs and sRAGE were analysed by fluorescence spectroscopy and competitive ELISA, respectively. Risk scores (GRACE, TIMI, PURSUIT) were calculated retrospectively using prospective data. The complexity of coronary artery disease was evaluated by SYNTAX score. RESULTS: The mean fluorescent AGEs and sRAGE levels were 57.7±45.1 AU and 1045.4±850.0 pg/mL, respectively. 19 patients presented cardiac events during in-hospital phase and 29 during the follow-up. In-hospital cardiac events were significantly associated with higher sRAGE levels (p = 0.001), but not long-term cardiac events (p = 0.365). Regarding fluorescent AGE the opposite happened. After multivariate analysis correcting by gender, left ventricular ejection fraction, glucose levels, haemoglobin, GRACE and SYNTAX scores, sRAGE was significantly associated with in-hospital prognosis, whereas fluorescent AGEs was significantly associated with long-term prognosis. CONCLUSIONS: We conclude that elevated values of sRAGE are associated with worse in-hospital prognosis, whereas high fluorescent AGE levels are associated with more follow-up events.
format Online
Article
Text
id pubmed-3772878
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37728782013-09-20 Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome Raposeiras-Roubín, Sergio Rodiño-Janeiro, Bruno K. Paradela-Dobarro, Beatriz Grigorian-Shamagian, Lilian García-Acuña, José M. Aguiar-Souto, Pablo Jacquet-Hervet, Michel Reino-Maceiras, María V. González-Juanatey, José R. Álvarez, Ezequiel PLoS One Research Article OBJECTIVE: Advanced glycation end products (AGEs) have pathophysiological implications in cardiovascular diseases. The aim of our study was to evaluate the prognostic value of fluorescent AGEs and its soluble receptor (sRAGE) in the context of acute coronary syndrome (ACS), both in-hospital phase and follow-up period. METHODS: A prospective clinical study was performed in patients with debut’s ACS. The endpoints were the development of cardiac events (cardiac deaths, re-infarction and new-onset heart failure) during in-hospital phase and follow-up period (366 days, inter-quartile range: 273–519 days). 215 consecutive ACS patients admitted to the coronary care unit (62.7±13.0 years, 24.2% female) were included. 47.4% had a diagnosis of ST segment elevation myocardial infarction. AGEs and sRAGE were analysed by fluorescence spectroscopy and competitive ELISA, respectively. Risk scores (GRACE, TIMI, PURSUIT) were calculated retrospectively using prospective data. The complexity of coronary artery disease was evaluated by SYNTAX score. RESULTS: The mean fluorescent AGEs and sRAGE levels were 57.7±45.1 AU and 1045.4±850.0 pg/mL, respectively. 19 patients presented cardiac events during in-hospital phase and 29 during the follow-up. In-hospital cardiac events were significantly associated with higher sRAGE levels (p = 0.001), but not long-term cardiac events (p = 0.365). Regarding fluorescent AGE the opposite happened. After multivariate analysis correcting by gender, left ventricular ejection fraction, glucose levels, haemoglobin, GRACE and SYNTAX scores, sRAGE was significantly associated with in-hospital prognosis, whereas fluorescent AGEs was significantly associated with long-term prognosis. CONCLUSIONS: We conclude that elevated values of sRAGE are associated with worse in-hospital prognosis, whereas high fluorescent AGE levels are associated with more follow-up events. Public Library of Science 2013-09-13 /pmc/articles/PMC3772878/ /pubmed/24058542 http://dx.doi.org/10.1371/journal.pone.0074302 Text en © 2013 Raposeiras-Roubín et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Raposeiras-Roubín, Sergio
Rodiño-Janeiro, Bruno K.
Paradela-Dobarro, Beatriz
Grigorian-Shamagian, Lilian
García-Acuña, José M.
Aguiar-Souto, Pablo
Jacquet-Hervet, Michel
Reino-Maceiras, María V.
González-Juanatey, José R.
Álvarez, Ezequiel
Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome
title Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome
title_full Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome
title_fullStr Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome
title_full_unstemmed Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome
title_short Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome
title_sort fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772878/
https://www.ncbi.nlm.nih.gov/pubmed/24058542
http://dx.doi.org/10.1371/journal.pone.0074302
work_keys_str_mv AT raposeirasroubinsergio fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome
AT rodinojaneirobrunok fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome
AT paradeladobarrobeatriz fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome
AT grigorianshamagianlilian fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome
AT garciaacunajosem fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome
AT aguiarsoutopablo fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome
AT jacquethervetmichel fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome
AT reinomaceirasmariav fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome
AT gonzalezjuanateyjoser fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome
AT alvarezezequiel fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome